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role of epigenetic?
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Abstract
Alzheimer disease (AD) is the most common neurodegenerative dementia. It leads to a progressive loss of
cognitive functions, especially memory. Most of AD cases are sporadic, resulting from the interplay of genetic
and environmental factors which get involved in the regulation of expression of thousands of genes, a mechanism
called epigenetic. Epigenetic modifications, by modifying genes transcription, help to orchestrate the phenotypical
changes linked to development, aging or even diseases and cancer. In AD, recent studies showed rapid, dynamic
and persistent epigenetic mutations that are believed to have consequences on brain functions. One of the
earliest biomarker of AD is amyloı¨d-beta (Aβ) deposition in the brain. According to current studies, deposition of
amyloı¨d-beta begins approximately 20 years before the first symptoms linked to the disease which questions
us about what could have happened around or before that time. In this exploratory study, we searched if there
could be any correlation between the experience of a strong psychologically stressful event in life, which could
have lead to several epigenetic changes and therefore the occurrence of Mild Cognitive Impairment (MCI) or
AD approximately 30 years later, and to see if there is a difference in the delay between amnestic MCI and AD
patients.
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Introduction
Alzheimer’s disease (AD) is the leading cause of dementia,
and the most prevalent neurodegenerative disease in the el-
derly. Demographic changes and the current absence of cure
for the disease cause the number of patients afflicted by de-
mentia worldwide to increase from 35.6 million in 2010 to
115.4 million in 2050 or even more according to recent studies
[1, 2]. AD is a progressive, irreversible disorder clinically
characterized by a progressive impairment in memory and
other cognitive abilities. At the microscopic level, the char-
acteristic lesions in Alzheimer’s disease are senile plaques,
due to amyloı¨d-beta protein (Aβ) aggregation and neurofibril-
lary tangles due to tau hyperphosphorylation, together with
a degeneration of the neurons and synapses due to neurovas-
cular dysfunction, and other mechanisms such as cell-cycle
abnormalities, inflammatory processes, oxidative stress, and
mitochondrial dysfunction, leading to massive neuronal loss,
mainly in the hippocampus and other associative regions of
the neocortex [3]. The studies of these brain changes and other
biological markers helped to know more about the chronolog-
ical sequences of AD, using brain Aβ amyloidosis (evaluated
by positron emission tomography (amyloid PET imaging),
elevated tau and phosphorylated tau and decreased Aβ in the
cerebrospinal fluid (CSF), decreased fluorodeoxyglucose 18F
(FDG) uptake on PET-scan with a medial temporal, poste-
rior cingulate and temporoparietal pattern of hypometabolism,
and brain atrophy on structural quantitative magnetic reso-
nance imaging (VBM voxel based morphometry MRI). All
of them are now used as biomarker of AD related changes,
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as shown in Fig. 1. Biomarkers are also contributing to the
clinical classification of the different phases of the disease
according to the revised criteria of 2011 [4] which also give a
chronological scale to the disease advances, as shown in Fig.
2. Although the neuropathological changes associated with
AD have been well characterized, there is still considerable
debate regarding the underlying etiology of the disorder and
the precise mechanism(s) that prevail behind disease progres-
sion. A genetic etiology has been found especially in early
onset AD ( <65 years old). Autosomal dominant mutations
in 3 genes (APP, PSEN1, and PEN2) are incriminated but
these genetic mutations account for only 5%–10% of the total
disease burden. Most cases of AD are at late onset (65 years),
non-Mendelian, and highly sporadic [5]. A genetic risk for
late onset AD remains ; the ε4 allele coding the apolipopro-
tein E (APOE), this allele increases the risk of the disease
by 3 times in heterozygotes and by 15 times in homozygotes.
It is thought to be one of the two main risk factors for AD
with increasing age [3]. Other susceptibility genes have been
reported by genome-wide association study (GWAS). They
all add quantitatively to an individual’s personal risk. Beside
genetic etiologies, emerging evidence from animal and hu-
man studies suggests that specific transcriptional mechanisms
including DNA methylation, histones modifications and chro-
matin remodeling, and non-coding RNA (ncRNA) regulation,
which determine how and when genes are expressed without
altering the genetic code, are contributing to AD. These mech-
anisms are known as epigenetic [6]. Studies on the expression
of memory-permissive genes regulation mechanisms showed
that epigenetic mechanisms are dynamic and reversible, sug-
gesting that the epigenome can be quickly altered in response
to experiential stimuli and that this epigenome can stably per-
sist throughout the lifespan [7, 8]. This information find its
interest in the fact that as epigenetic changes affect genes tran-
scription mechanisms, their effects can give rise to different
cell types and developmental stages, and be either favorable,
unfavorable or neutral for specific cells within the same organ
system that can have an impact on the life of an individual.
For example, increasing the accessibility of a gene regula-
tory element could either increase or decrease transcription of
nearby genes depending on whether an activator or a repressor
binds at that site. We can easily understand then how complex
research in that field becomes, especially now that it is known
that epigenetic changes can be induced by different environ-
mental, or simply stochastic events, as it is showed by an
increasing number of studies in many different medical fields
(Millington, 2008: UV and cutaneous malignancies; Zannas
and West, 2014: psychiatric disorders; etc.) [9, 10]. Specific
studies about learning and memory confirmed (in vitro) that
there is a functional role of DNA methylation and histones
acetylation in spontaneous neurotransmission and short-term
synaptic plasticity in the acquisition and persistence of altered
behavioral responses of the organism to an environmental
stimulus [11]. Moreover, it has been shown that dynamic
regulation of gene expression by epigenetic mechanisms is a
necessary and critical process in the formation, storage and
recall of memory and subsequent behavior. Indeed DNA
methylation and phosphorylation changes are essential for the
formation of LTM (long term memory), consolidation and
recall memory. Likewise, there is growing evidence showing
that histones acetylation have also effects on memory and
behavior, especially LTM [12]. These changes are observed
in the hippocampus, amygdala and cortex in response to learn-
ing which are also the anatomical regions involved in AD
pathology [7, 13, 14, 15]. Such discoveries about epigenetic
outcomes and memory regulation speak for a probable link
between epigenetic changes and AD and underline the diffi-
culty to link a specific mechanism to a specific outcome.
One possible etiology of epigenetic changes and memory
function is mental stress. As memories are built on the envi-
ronment, they play a crucial part of how we adapt to changes in
the environment thereby preparing us cognitively, emotionally,
and physiologically to all kind of life events. We know that we
make particularly strong memories of traumatically stressful
events in our lives, therefore, strong psychologically stressful
events are crucial in their impact on survival and inclined to
have a long-lasting impact on behavior [16, 17]. The behav-
ioral responses to stressful events involves changes in gene
expression in limbic and paralimbic brain regions such as the
hippocampus and amygdala and cingulate gyrus, once again,
the brain regions that are more fragile in AD. A vicious circle
exists between early-life adversity, hypothalamic-pituitary-
adrenal axis regulation - therefore stress response - and future
chronic stress, which acts through epigenetic mechanisms to
reprogram expression patterns of the glucocorticoı¨d recep-
tors, therefore influencing the sensitivity of an individual’s
response to environmental stressors. In brief, life experi-
ence modifies the epigenome, and as epigenome is related
to memory-related gene expression, it means that experience
through life events are critical for the plasticity that occurs
in response to learning and memory [7]. Following what we
know about chronological brain changes in AD and the strong
impact of psychologically stressful events on the epigenome,
we worked on an exploratory qualitative study, aiming to de-
termine if there is a correlation between the experience of a
traumatic life event and the occurrence of amnestic MCI and
AD, or if it exists a restricted critical time interval between
the event and the onset of symptoms. In a more clinical goal
we will try to give arguments on the interest of taking the
past psychological life events history of patient coming with
memory complaint. Could this be of future use for a better
approach and understanding of the environmental factors in
the beginning of MCI and AD disorders?
1. Methods
1.1 Subjects
Our qualitative study is based on 45 telephonic interviews.
30 patients were recruited between 2013 and 2014 from the
“Leenaards Memory Center of the CHUV, Lausanne”, accord-
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Figure 1: Hypothetical model of the dynamic of biomarkers in AD development [18].
ing to the revised criteria of 2011 for diagnosis of AD [4]. 15
patients with known incipient Alzheimer dementia (clinical
dementia rating, CDR of 0.5-1) were selected, 15 with amnes-
tic MCI (executive dysfunction allowed), and 15 control cases,
with no complaint nor sign of cognitive impairment or psychi-
atric disorder. All the subjects were older than 50 years, and
MMS score was available for the 30 patients recruited at the
“Leenaards Memory Center”. Familial cases were rejected in
order to focus on patients with a sporadic form of AD.
1.2 Telephonic interviews
Our questionnaire can be found in the appendix section of this
paper. The purpose of this questionnaire was to investigate
the occurrence of traumatic life events in patients and control
cases through one open question (the interviewed person recall
spontaneously the traumatic event) and the following proposed
list of traumatic events:
• serious accident or wound
• mental or physical violence
• sexual abuse
• painful mourning
• divorce/separation/infidelity
• being witness of a catastrophe
• facing a difficult diagnosis
• difficult treatment/operation/hospitalization
• death Note
• missing person
• serious financial problem
• trouble with justice
• dismissal/unemployment/professional threat
• deportation
• psychiatric disorder
• other not mentioned
The primary idea was to focus on traumatic events that oc-
curred around 20 years before the first symptoms of the dis-
ease, as it has been shown that it is the approximate lapse of
time between the first appearance of pathological changes of
AD and these first symptoms [18], but due to the difficulty
to recall the exact year of the events, we choose to split the
events into two categories: events that happened more than
30 years and events that happened less than 30 years before
today (2014). The dates of symptoms onset were found in
patients medical records. The ethical comity did not show
any concern regarding our study, as all the participants gave
their enlighten consent to participate to the interviews which
were made only because these items were insufficiently re-
ported either in details or even at all mentioned in previous
summaries of the personal and social history of their charts.
These interviews are considered as “further patient history”.
If we can prove that history of traumatic life-events can be of
any help for treatment or early diagnosis of AD, then this kind
of interview could become a part of patients medical folder
for more analysis.
1.3 Data analysis
If we know the approximate time of pathological changes (Aβ
deposition and tau hyperphosphorylation), approximately 20
years before the first symptoms of AD, it is more difficult to
find in the literature any strong timing correlation between epi-
genetic changes and the onset of the disease. Indeed, studies
showed that epigenetic changes following stress does not af-
fect the accumulation of Aβ nor tau [20]. It is also known that
some epigenetic changes that happened in early childhood are
creating a predisposition to certain diseases, such as depres-
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Figure 2: Theoretical model of cognitive and biological markers
progression in AD. In this model, we can see that there is approxi-
matively 5 years between the first memory symptoms, marking the
beginning of MCI phase, and the development of dementia [19].
sion or cancer, later on. This is the reason why we chose to
extend the investigation of traumatic life-events to the whole
patient life, and separated the data into two categories, “events
that happened more than 30 years from now” and “events that
happened less than 30 years from now”. Knowing the year of
symptoms onset in MCI and AD patients and the date when
the traumatic event happened, we calculated another vari-
able that we called “latency”. “Short latency” encompasses
traumatic events that happened after 1984, as “Long latency”
encompasses traumatic events that happened before 1984.
1.4 Statistical analysis
All analyses were performed using STATA. Statistics have
been mostly performed on data coming from the two groups of
persons having a known MMS score (MCI and AD patients),
which means all the statistical analysis found in tables 1 to
3 are based on only 30 patients. In table 1, MMS score has
been used as a dependent variable, as every traumatic event
was considered as an independent variable for the analysis
of variance (ANOVA), which is used to compare two groups.
Considering that MMS score has not a normal distribution,
a cubical transformation has been applied. These statistical
analyses have also been performed using the illness dura-
tion as a confounding variable, therefore adjusting the MMS
scores for all the patients, as if all of them had been analyzed
with the same time-span of the disease (hypothesizing a linear
evolution with time). This allows to easily identify a possible
correlation to the traumatic events. Considering the small
number of patients, no more confounding variables have been
applied.
Willing to flesh out our initial results, we used another
variable, the latency (described earlier in data analysis), to
assess the effect of traumatic life events on the worsening
of the MMS score, reflecting indirectly the phase of the dis-
ease (MCI or AD). The distribution of this variable being
normal, no transformation was needed this time. Finally, we
performed a correlation analysis, using the Pearson’s Coeffi-
cient, in order to compare the effect of different variable on
the MMS score (see table 3).
A statistical result can be considered as significant when
p-value ≤ 0.05.
2. Results
All events confounded, statistics didn’t show any significant
difference between control cases group and MCI or AD group
regarding the number of traumatic event experimented in
life regardless of their chronology. Out of 106 memories of
traumatic life events, 22 were recalled by control cases, 40 by
MCI patients and 44 by AD patients.
Statistics testing the correlation between the experience
of a traumatic life event and the MMS score didn’t show any
significant results (see table 1). None of the traumatic events
happened to worsen significantly the MMS of patients (MCI
and AD confounded) having experienced it, which denies our
hypothesis that traumatic events are triggering the neurode-
generative changes. Surprisingly, results showed quite the
contrary, as it seems, according to our data, that there is a
small tendency for physical abuse and psychiatric disorder
of being protective against a worsening in MMS score, the
MMS score of these patients being higher than the one that
has not experienced those two traumatic events. However,
these results should be interpreted with caution, the numbers
of measure being so few (n=2 for physical abuses, n=8 for
psychiatric disorders). When non adjusted, the results are
even less significant. As seen earlier in statistical analysis, the
hypothesis of a linear evolution of the disease with time was
made when adjusting the MMS to the illness duration.
When comparing average age and MMS between the
groups, we noticed that AD patients are significantly older
than control cases (p ≤ 0.05) and MCI patients have a signifi-
cantly higher MMS score than AD ones. These two observa-
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NEGATIVE ANSWER POSITIVE ANSWER p
MCI+AD MMS MCI+AD MMS Not Adjusted Adjusted
Spontaneously recalled events (all to-
gether)
13 (43%) 17 (57%)
Spontaneously recalled events after 1984 20 (67%) 22.8 ± 6 10 (33%) 25.0 ± 3.5 0.2693 0.8061
Spontaneously recalled events before
1984
20 (67%) 23.5 ± 5 10 (33%) 23.9 ± 6 0.6638 0.5934
Serious accident 28 (93%) 23.8 ± 4 2 (7%) 20.0 ± 13 0.6973 0.5621
Mental/physical violence 28 (93%) 23.3 ± 5 2 (7%) 26.3 ± 4 0.2325 0.0336
Sexual abuse 29 (97%) 23.6 ± 5 1 (3%) 24.0 0.9010 0.6146
Painful mourning 9 (30%) 24.6 ± 3 21 (70%) 23.1 ± 6 0.6152 0.7379
divorce/separation/infidelity 22 (73%) 23.9 ± 4 8 (27%) 22.9 ± 7 0.8684 0.4061
Being witness of a catastrophe 27 (90%) 24.2 ± 4 3 (10%) 18.3 ± 9 0.1067 0.2041
Facing a difficult diagnosis 25 (83%) 23.5 ± 5 5 (17%) 24.5 ± 2 0.9612 0.4617
Difficult treatment / operation / hospital-
ization
22 (73%) 24.7 ± 3 8 (27%) 19.3 ± 8 0.0651 0.2257
Death Note 30 (100%) 23.6 ± 5 0 (0%) / / /
Missing person 30 (100%) 23.6 ± 5 0 (0%) / / /
Trouble with justice 29 (97%) 23.4 ± 5 1 (3%) 28.0 0.2647 0.2680
Serious financial problem 28 (93%) 23.3 ± 5 2 (7%) 28.5 ± 1 0.0556 0.0559
Dismissal / unemployment / professional
threat
24 (80%) 23.5 ± 5 6 (20%) 24.0 ± 4 0.9205 0.3522
Deportation 27 (90%) 23.5 ± 5 3 (10%) 24.5 ± 4 0.7417 0.1547
Psychiatric disorder 22 (73%) 22.7 ± 5 8 (27%) 26.0 ± 3 0.0696 0.0162
Other not mentioned 29 (97%) 23.5 ± 5 1 (3%) 24.0 0.9946 0.2049
Table 1: Correlation between the experience of a traumatic life event and the MMS score. MMS scores underwent a cubical transformation
in order to obtain a normal distribution and were adjusted, using the illness duration.
NC MCI AD p
Age [years] 70.0 ± 11.0 72.8 ± 11.9 80.9 ± 9.2
MMS 28.0 21.0
Short Latency (pg 1984) [years] 13.8 ± 8.8 21.0 ± 5.3 0.148
Long Latency (pp 1984) [years] 52.2 ± 16.4 56.5 ± 13.4 0.68
Table 2: Age and MMS comparison between groups. Difference of latencies between MCI and AD.
Predictive Variable Pearson’s Coefficient p
Age -0.401692981 0.03
Illness Duration 0.107694305 0.57
Short Latency 0.289545137 0.19
Long Latency -0.129824222 0.63
Table 3: MMS prediction by some other variables. MMS score underwent a cubical transformation in order to obtain a normal distribution.
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tions have their interest in the interpretation of other results.
About the statistical tests on latency (see table 2), results show
that there is a slight tendency for the events that happened
13 years before the onset of symptoms of MCI patient, and
21 years before the onset of symptoms of AD patient (also
known as “short latency”), to be associated with MCI and
AD with a difference of approximately 8 years between the
two phases of the disease. But after performing a correlation
analysis (see table 3) with age and illness duration as compar-
ative variables, we noticed that out of long and short latencies,
age and illness duration, only the age can predict significantly
a worsening in the MMS score (p = 0.03), which suggests
that the latency, especially the shorter one, does not or very
slightly predict the worsening of MMS score. In other words,
the significant result found in table 2 for short latency might
be mainly attributed to age, which is the only variable that
proved itself to worsen the MMS score of patients.
3. Discussion
On the overall, one of our main limitation in this study was
the small number of participants and therefore data to analyze.
But many other bias, approximations and malpractices can be
discussed in all the phases of this exploratory study, leading
to a lack of accuracy in our results. This discussion aims to
bring out some of the problems we encountered while talking
of the results we obtained and giving some idea for the design
of future studies in the field.
First of all, it has to be noticed that our statistical analysis
didn’t take into account the multiple experience of a same
kind of traumatic event (for instance, the experience of three
different painful mourning). Only the number of individual
recalling events was used in the statistics (n = 71) as the to-
tal number of traumatic events recalled (n = 161) was not.
This is a mistake, as it has been described in several studies
that chronic distress (that could be due to an accumulation
of acute or subacute traumatic life events) may compromise
the structure and function of key areas of the hippocampal
formation and other limbic regions so that less age-related
pathology would be needed to cause dementia [20]. Indeed,
the behavioral responses to stressful events involves changes
in gene expression in limbic brain regions such as the hip-
pocampus. As mentioned in the introduction, a vicious circle
exists between early-life adversity, stress response and future
chronic stress, which influences the individual proneness to
distress [7], underlying once again the interest to integrate
the multiple experience of a same kind of traumatic event in
the statistical analysis.This being said, we can talk about the
statistics we actually performed.
The first important thing to say is that out of 30 patients,
if a correlation between the experience of a traumatic event
in life and the occurrence of AD was obvious, it would have
been shown in the results. The fact that they did not show
anything but slight tendencies can signified two things: either
there is no correlation between the experience of a traumatic
event in life and the development of AD later on, either there
is a very slight tendency only, which we could explore with
other studies, with specific, more adapted design and more
patients.
About the results presented in table 1, it is clear that there
is no correlation between the experience of a traumatic life
event and a worsening in MMS scores, quite the contrary,
with a very small tendency for physical abuse and psychiatric
disorder of being protective against a worsening in MMS
score which could be interpreted as a “protective effect” due
to repetitive stress. We saw earlier that we must stay cautious
with these results, first, because the number of data is very
small, second, because these results could be due to the status
of the patients themselves, as patients with lower MMS may
not remember having suffered from physical abuse, or are
just being less conscious of their psychiatric disorder. Our
statistician also warned us against the probability of false
positive (type I mistakes) which occurs when a high number
of statistical tests are performed on very few measures.
Results presented in table 1, more than ruling out a po-
tential impact of traumatic event on the development of AD,
questioned us about our way to analyze data, using the MMS
as a defined variable. Indeed, the MMS, because it can be
affected by so many other causes, the most important one be-
ing old age, doesn’t help in the diagnosis of AD and therefore
in the separation of our two groups of patients. It remains a
clinical tool to assess progression and severity in dementia,
all kind confound, not only AD, which is the reason why, we
must be cautious about the interpretation of our results, as we
approximate that AD was related to a lower MMS score. This
approximations was based on the results in table 2, showing
that AD patients are significantly older than control cases and
that MCI have a significantly higher MMS score than AD.
It is in table 2 that we find a slight argument for a po-
tential impact of the experience of a traumatic life event on
the development of AD. Indeed, despite a few number of par-
ticipants our results showed a small significant tendency for
events that happened 13 years before the onset of symptoms
in MCI patients, and 21 years before the onset of symptoms
in AD patients of being associated with the development of
the disease. With a difference of 7 years between MCI stage
and AD, latency that correspond to the usual latency between
this two stages of the disease as shown in Figure 2. Statistics
also showed that this study was not powerful enough with 15
patients in each group to obtain significant results. According
to this analysis, we should have interviewed 18 patients in
each group to improve our results. According to this analysis,
we should have interviewed> 18 patients (ideally 25), in each
group to improve our results. Further studies would therefore
be needed in order to support this tendency. Once again, a
criticism can be made about our study design, because of the
way we selected our participants. Indeed, in our approxima-
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tion, we considered that all the MCI can progresses to AD,
which is not the case in reality, where studies showed that the
majority of diagnosed MCI does not progress to dementia,
even after a 10 years follow-up [21].
Last but not least, it seems, according to our correlation
analysis (see table 3), that the small tendency found in table
2 for short latency might be mainly attributed to age, which
is, as we have seen before, one of the two main risk factor for
the development of AD and of great influence in worsening
the MMS score of individuals.
While going through our results, other bias were brought
out. We discuss them below, separating them into pre-trial
bias and clinical trial bias.
Our qualitative study being an exploratory one in the ques-
tion of the epigenetic related outcomes in AD after the experi-
ence of traumatic life events, it encountered several so-called
pre-trial bias during the study design. For instance the def-
inition of risk (having experienced a traumatic event) and
outcome (development of AD, which is itself a pathology for
which the diagnosis cannot be certain until death and anatomo-
pathological examination), which should be clearly defined,
could not be in our work. We noticed for instance, after fin-
ishing our interviews phase of the study, that we should have
been more accurate in our definition of “traumatic life event”.
Indeed, such subjective measure can have a high interpersonal
variability and arbitrary cutoffs (for instance determine when
a mourning become traumatic) makes the distinction between
groups difficult (who is “traumatized” who is not?). Accord-
ing to Pannucci and Wilkins [22], this can inflate the observed
variance seen with statistical analysis, making a statistically
significant result less likely. This observation makes sense in
our study, our results showing only slight tendencies (p 
0.05). A standardized protocol for data collection with train-
ing of the interviewer (us) could have minimized the impact of
this bias. For instance, we could have used known DSM crite-
ria to evaluate the “degree of traumatism” of our participants,
or even more standardized, as it has been already used in sev-
eral studies, using the measure of neuroticism, which has been
proved to be a stable indicator of proneness to psychological
distress (because they inclined to mental disorders through
epigenetic mechanisms). Indeed, according to studies using
data from “the Rush Memory and Aging Project”, persons
with a high level of distress proneness are 2.7 times more
likely to develop AD than those not prone to distress [20].
With a measure of neuroticism we would have improved the
accuracy of our results, by giving a higher value to the effect
of a traumatic event on a person and not just the presence or
not of an event in life.
Another well known pre-trial bias is the selection bias. It
happens when exposure and outcome have already occurred
at the time individuals are selected for study inclusion, which
is the case in our study, where we asked known MCI or AD
patients to recall the potential experience of traumatic events
in their life.
About clinical trial bias we can say that the one which
influenced the most our collection of data was the interviewer
bias. It refers to a systematic difference between how informa-
tion is solicited, recorded or interpreted. In our case, even with
the same questionnaire, we could sense a difference between
how the two interviewers were performing. The way they
decided to determine if a painful mourning was considered as
“traumatic” or not, or their different definition of a “traumatic
psychiatric disorder”, etc. was completely subjective. These
differences could also been sense between interviews made
by the same interviewer.
4. Conclusion
In the overall, our results didn’t show any statistically signifi-
cant correlation between the experience of a traumatic event
in life and a worsening of the MMS later on. Due to the lack
of power in statistical analysis, the low internal validity of
our exploratory study due to the numerous bias involved, and
the ambivalence of some of our results, we cannot conclude
anything firmly about the impact of strong psychologically
stressful events on the development of Alzheimer disease
through epigenetic mechanisms
Nowadays, we tend not to consider AD as a “disease”
anymore, but as a more complex entity, including multifacto-
rial conditions, supported by several pathological processes,
partially independent, but also interacting one with another,
being under the influence of several risk factors, specific, as ε4
allele coding for APOE for instance, but also very unspecific,
such as environmental factors which influence the epigenome
in many different ways. The difficulty to link a specific brain
change to a specific etiological agent in AD pathology, is lead-
ing researchers to think through AD all over again, bringing
out new hypothesis such as the growing evidences that the
neuropathological changes in brain found in AD correspond
to a variable host response which could be a protective an-
swer of the brain to an underlying etiology [23, 24]. Other
optimistic studies about epigenetic processes in brain showed
that cognitive capacities following neurodegeneration should
not be considered as lost but simply impaired by epigenetic
modifications of gene transcription, which gives the future of
therapeutic drug research for AD a radiant prospect [25, 26].
As for the interest of including the history of traumatic
life events in patients complaining of cognitive ongoing symp-
toms, we would say that using a standardized protocol for
data collection such as the degree of neuroticism, which was
already used in other studies [20], together with the investi-
gation of the level of distress proneness, would be of more
use than a simple listing of potentially traumatic events in
order to detect patients at higher risk to develop neurodegener-
ative diseases such as AD and introduce earlier management,
such as specific therapeutic drugs working on the memory
reconsolidation process [17].
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Appendix
Bonjour, mon nom est Fabio Schipani / Sarah El-Achachi, je
suis e´tudiant(e) en me´decine en 5e anne´e, actuellement en
plein travail de maıˆtrise sur la maladie d’Alzheimer. Je tra-
vaille en partenariat avec les Professeurs Ghika et Demonet de
la Consultation Leenards du CHUV, qui ont duˆ vous informer
de notre appel et s’assurer de votre consentement. Cette in-
terview restera strictement anonyme dans le respect du secret
professionnel auquel je suis tenu(e) en tant qu’e´tudiant(e) en
me´decine. La dure´e maximale de cette interview est de 10 mi-
nutes. Eˆtes-vous toujours d’accord d’y participer en re´pondant
a` nos questions ?
Les questions que je vais vous poser sont relatives aux e´ve´nements
traumatiques que vous auriez pu ou non expe´rimenter durant
votre vie. En effet, notre recherche se focalise sur ceux-ci,
notre hypothe`se e´tant qu’ils pourraient eˆtre a` l’origine de
changements dans le cerveau.
1. Avez-vous le souvenir d’avoir ve´cu un (ou plusieurs)
e´ve´nement(s) traumatisant(s) durant ces 30 dernie`res
anne´es (depuis 1980 environ) ? Si oui, quand a-t-il (ont-
ils) eu lieu ?
2. Je vais a` pre´sent vous citer diffe´rents e´ve´nements poten-
tiellement traumatisants. Dites-moi si vous avez ve´cu
l’un ou plusieurs d’entre eux, toujours si ils ont eu lieu
durant ces 30 dernie`res anne´es :
• Un accident grave ou des blessures graves ? Si oui
quand ?
• Des violences physiques ou mentales ? Si oui
quand ?
• Une agression sexuelle ? Si oui quand ?
• Le de´ce`s d’un proche ou un deuil difficile ? Si oui
quand ?
• Un divorce, une se´paration, un abandon ou une
infide´lite´ qui vous aie marque´(e) ? Si oui quand ?
• Avoir e´te´ te´moin d’un accident grave ou d’une
catastrophe ? Si oui quand ?
• Avoir rec¸u un diagnostic grave ? Si oui quand ?
• Avoir ve´cu un traitement/ope´ration/hospitalisation
difficile ? Si oui, quand ?
• Une menace de mort (directe ou indirecte) ? Si
oui, quand ?
• Une disparition ? Si oui, quand ?
• Un proble`me financier grave ou une faillite ? Si
oui, quand ?
• Un proble`me avec la justice ? Si oui quand ?
• Un licenciement, un choˆmage, ou une menace
professionnelle ? Si oui, quand ?
• Un e´loignement a` l’e´tranger ? Si oui, quand ?
• Un proble`me psychiatrique ? Si oui quand ?
• Un autre e´ve´nement que nous n’aurions pas men-
tionne´ ? Si oui, quand ?
(Pour chaque oui :) Souhaiteriez-vous en parler brie`vement ?
3. Lors des e´preuves, vous aidez-vous d’une croyance re-
ligieuse ou autre ?
Avant de terminer, avez-vous des questions ou souhaitez-
vous ajouter quelque chose ?
Nous sommes arrive´s a` la fin de notre questionnaire,
je vous remercie pour votre collaboration et votre dis-
ponibilite´. Si vous eˆtes inte´resse´s par les re´sultats de
notre travail, nous vous communiquerons nos re´sultats
lorsque ceux-ci auront e´te´ re´dige´s. Merci et bonne fin
de journe´e.
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